Targeting insulin-like growth factor pathways

Br J Cancer. 2006 Feb 27;94(4):465-8. doi: 10.1038/sj.bjc.6602963.


Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor
  • Clinical Trials as Topic
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology*
  • Receptor, IGF Type 1 / drug effects*
  • Receptor, IGF Type 1 / physiology*
  • Research Design
  • Signal Transduction


  • Biomarkers, Tumor
  • Receptor, IGF Type 1